NEW BRUNSWICK, N.J.,
Oct. 13, 2020 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced results
for third-quarter 2020. "Our third-quarter results reflect
solid performance and positive trends across Johnson & Johnson,
powered by better-than-expected procedure recovery in Medical
Devices, growth in Consumer Health, and continued strength in
Pharmaceuticals," said Alex Gorsky,
Chairman and Chief Executive Officer. "I am proud of the relentless
passion and Credo-led commitment to patients and customers that our
colleagues around the world continue to demonstrate as we boldly
fight the COVID-19 pandemic. Our world-class R&D team is
working tirelessly to advance the Phase 3 trials of our COVID-19
vaccine and to uphold the highest standards of transparency, safety
and efficacy; while other dedicated teams provide ongoing support
to hospitals and patients as they return to sites of care, and
ensure patients and consumers have the medicines and products they
need. This resilient mindset, combined with our strategic
capabilities and execution excellence, increase our optimism for
continued recovery in 2020 and strong momentum entering into
2021."
OVERALL FINANCIAL RESULTS:
|
THIRD
QUARTER
|
|
($ in Millions,
except EPS)
|
2020
|
2019
|
%
Change
|
Reported
Sales
|
$ 21,082
|
$ 20,729
|
1.7%
|
Net
Earnings
|
3,554
|
1,753
|
102.7%
|
EPS
(diluted)
|
$
1.33
|
$
0.66
|
101.5%
|
|
|
|
|
Non-GAAP*
|
THIRD
QUARTER
|
|
($ in Millions,
except EPS)
|
2020
|
2019
|
%
Change
|
Operational
Sales1,2
|
N/A
|
N/A
|
1.7%
|
Adjusted
Operational Sales1,3
|
N/A
|
N/A
|
2.0%
|
Adjusted Net
Earnings1,4
|
5,868
|
5,672
|
3.5%
|
Adjusted EPS
(diluted)1,4
|
$
2.20
|
$
2.12
|
3.8%
|
|
1 Non-GAAP
financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
|
2 Excludes
the impact of translational currency
|
3 Excludes
the net impact of acquisitions and divestitures and translational
currency
|
4 Excludes
intangible amortization expense and special items
|
REGIONAL SALES RESULTS:
|
THIRD
QUARTER
|
%
Change
|
($ in Millions) 1
|
20202
|
20192
|
Reported2
|
Operational1,2
|
Currency2
|
Adjusted
Operational1,3
|
U.S.
|
$ 11,086
|
$ 10,791
|
2.7%
|
2.7%
|
-
|
2.8
|
International
|
9,996
|
9,938
|
0.6%
|
0.6%
|
0.0
|
1.1
|
Worldwide
|
$ 21,082
|
$ 20,729
|
1.7%
|
1.7%
|
0.0
|
2.0
|
|
1 Non-GAAP
financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
|
2 Excludes
the impact of translational currency
|
3 Excludes
the net impact of acquisitions and divestitures and translational
currency
|
Note: values
may have been rounded
|
SEGMENT SALES RESULTS:
|
THIRD
QUARTER
|
%
Change
|
($ in Millions) 1
|
20201
|
20191
|
Reported2
|
Operational1,2
|
Currency1
|
Adjusted
Operational1,3
|
Consumer
Health
|
$
3,514
|
$
3,469
|
1.3%
|
3.0
|
(1.7)
|
3.1
|
Pharmaceutical
|
11,418
|
10,877
|
5.0%
|
4.6
|
0.4
|
4.7
|
Medical
Devices
|
6,150
|
6,383
|
(3.6)%
|
(3.9)
|
0.3
|
(3.3)
|
Worldwide
|
$
21,082
|
$
20,729
|
1.7%
|
1.7
|
0.0
|
2.0
|
|
1 Non-GAAP
financial measure; refer to reconciliations of non-GAAP financial
measures included in accompanying schedules
|
2 Excludes
the impact of translational currency
|
3 Excludes
the net impact of acquisitions and divestitures and translational
currency
|
Note:
values may have been rounded
|
SEGMENT COMMENTARY:
Consumer Health
Consumer Health worldwide operational
sales, excluding the net impact of acquisitions and divestitures,
increased by 3.1%*, inclusive of the net negative impact of
COVID-19 primarily in international over-the-counter
products. Sales growth was driven by U.S. growth in
over-the-counter products including TYLENOL analgesics and
digestive health products; LISTERINE mouthwash in oral care
products; OGX in skin health/beauty products; and wound care
products, primarily BAND-AID® Brand Adhesive Bandages.
Pharmaceutical
Pharmaceutical worldwide operational
sales, excluding the net impact of acquisitions and divestitures,
grew 4.7%* driven by DARZALEX (daratumumab), for the treatment of
multiple myeloma, STELARA (ustekinumab), a biologic for the
treatment of a number of immune-mediated inflammatory diseases,
IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use
in treating certain B-cell malignancies, a type of blood or lymph
node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA
(paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults,
OPSUMIT (macitentan), an oral endothelin receptor antagonist
indicated for the treatment of pulmonary arterial hypertension to
delay disease progression, UPTRAVI (selexipag), an oral
prostacyclin receptor agonist used to treat pulmonary arterial
hypertension and reduce hospitalization, and ERLEADA (apalutamide),
a next-generation androgen receptor inhibitor for the treatment of
patients with prostate cancer. This growth was partially offset by
the negative impact of COVID-19 as well as biosimilar and generic
competition, with declines primarily in REMICADE (infliximab), a
biologic approved for the treatment of a number of immune-mediated
inflammatory diseases, and ZYTIGA (abiraterone acetate), an oral,
once-daily medication for use in combination with prednisone for
the treatment of metastatic castration-resistant prostate
cancer.
Medical Devices
Medical Devices worldwide operational
sales, excluding the net impact of acquisitions and divestitures,
declined by 3.3%*. The decline was primarily driven by the
negative impact of the COVID-19 pandemic and the associated
deferral of medical procedures to our Surgery, Orthopaedics, and
Vision businesses. Results reflect market recovery versus the
second quarter. The decline was partially offset by growth in the
Interventional Solutions business led by electrophysiology
products.
NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:
The
information contained in this section should be read in conjunction
with Johnson & Johnson's other disclosures filed with the
Securities and Exchange Commission, including its Current Reports
on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on
Form 10-K. Copies of these filings are available online at
www.sec.gov, www.jnj.com or on request from Johnson & Johnson.
The reader is also encouraged to review all other news releases
available online in the Investors section of the Company's website
at news releases.
Regulatory
Approvals
|
THERMOCOOL SMARTTOUCH
– Biosense Webster Receives FDA Approval for SF Ablation Catheter
for the Treatment of Persistent Atrial Fibrillation¹
|
(press
release)
|
SIMPONI ARIA
(golimumab) – Approved by the U.S. Food and Drug Administration for
Active Polyarticular Juvenile Idiopathic Arthritis and Extension of
Its Active Psoriatic Arthritis Indication in Patients 2 Years of
Age and Older
|
(press
release)
|
SPRAVATO (esketamine)
– Janssen Announces U.S. FDA Approval of CIII Nasal Spray to Treat
Depressive Symptoms in Adults with Major Depressive Disorder with
Acute Suicidal Ideation or Behavior
|
(press
release)
|
DARZALEX
(daratumumab) – U.S. FDA Approves New DARZALEX-Based Combination
Regimen for Patients with Relapsed/Refractory Multiple
Myeloma
|
(press
release)
|
|
STELARA (ustekinumab)
– U.S. Food and Drug Administration Approves Treatment of Pediatric
Patients with Moderate to Severe Plaque Psoriasis
|
(press
release)
|
Regulatory
Submissions
|
UPTRAVI (selexipag) –
Janssen Submits New Drug Application (NDA) to U.S. FDA for
Injection for Intravenous Use to Treat Pulmonary Arterial
Hypertension (PAH)
|
(press
release)
|
|
DARZALEX FASPRO
(daratumumab and hyaluronidase-fihj) – Janssen Submits Application
Seeking U.S. FDA Approval for the Treatment of Patients with Light
Chain (AL) Amyloidosis
|
(press
release)
|
Other
|
Johnson & Johnson
Announces European Commission Approval of Agreement to Supply 200
Million Doses of Janssen's COVID-19 Vaccine
Candidate ¹
|
(press
release)
|
Johnson & Johnson
Completes Acquisition of Momenta Pharmaceuticals, Inc.¹
|
(press
release)
|
Johnson & Johnson
Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's
COVID-19 Vaccine Candidate
|
(press
release)
|
CERENOVUS Launches
New Suite of Technologies to Advance Stroke Treatment
|
(press
release)
|
Johnson & Johnson
Announces that Janssen's COVID-19 Investigational Vaccine Candidate
Prevents Severe Clinical Disease in Pre-clinical Studies
|
(press
release)
|
Janssen to
Discontinue Pimodivir Influenza Development Program
|
(press
release)
|
Johnson & Johnson
Announces Agreement with U.S. Government for 100 Million Doses of
Investigational COVID-19 Vaccine
|
(press
release)
|
U.S. FDA Grants
Ethicon Breakthrough Device Designation for Monarch-enabled NeuWave
Microwave Ablation Technology
|
(press
release)
|
|
1
Subsequent to the quarter
|
FULL-YEAR 2020 GUIDANCE:
Johnson & Johnson does
not provide GAAP financial measures on a forward-looking basis
because the Company is unable to predict with reasonable certainty
the ultimate outcome of legal proceedings, unusual gains and
losses, acquisition-related expenses and purchase accounting fair
value adjustments without unreasonable effort. These items are
uncertain, depend on various factors, and could be material to
Johnson & Johnson's results computed in accordance with
GAAP.
The estimated impact of the COVID-19 pandemic is included in the
guidance below.
|
October
2020
|
July
2020
|
|
|
|
($ in Billions,
except EPS)
|
|
|
Adjusted Operational
Sales1,2
Change vs. Prior
Year
|
0.5% –
1.5%
|
(0.8%) –
1.0%
|
Operational
Sales2
Change vs. Prior
Year
|
$82.0 to
$82.8
0.0% –
1.0%
|
$81.0 to
$82.5
(1.3%) –
0.5%
|
Estimated Reported
Sales3
Change vs. Prior
Year
|
$81.2 to
$82.0
(1.0%) –
0.0%
|
$79.9 to
$81.4
(2.6%) –
(0.8%)
|
|
|
|
Adjusted Operational
EPS (Diluted)2,4
Change vs. Prior
Year
|
$7.95 to
$8.05
(8.4%) -
(7.3%)
|
$7.85 to
$8.05
(9.6%) -
(7.3%)
|
Adjusted EPS
(Diluted)3,4
Change vs. Prior
Year
|
$7.95 to
$8.05
(8.4%) –
(7.3%)
|
$7.75 to
$7.95
(10.7%) –
(8.4%)
|
|
1 Non-GAAP
financial measure; excludes the net impact of acquisitions and
divestitures
|
2 Non-GAAP
financial measure; excludes the impact of translational
currency
|
3
Calculated using Euro Average Rate: October 2020 = $1.14 Euro
Average Rate: July 2020 = $1.12 (Illustrative purposes
only)
|
4
Non-GAAP financial measure; excludes intangible amortization
expense and special items
|
Other modeling considerations will be provided on the
webcast.
WEBCAST INFORMATION:
Johnson & Johnson will
conduct a conference call with investors to discuss this earnings
release today at 8:30 a.m., Eastern
Time. A simultaneous webcast of the call for investors and
other interested parties may be accessed by visiting the Johnson
& Johnson website. A replay and podcast will be available
approximately two hours after the live webcast in the Investors
section of the Company's website at
events-and-presentations.
ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
NON-GAAP FINANCIAL MEASURES:
*Operational sales growth
excluding the impact of translational currency, adjusted
operational sales growth excluding the net impact of acquisitions
and divestitures and translational currency, as well as adjusted
net earnings, adjusted diluted earnings per share and adjusted
operational diluted earnings per share excluding after-tax
intangible amortization expense and special items, are non-GAAP
financial measures and should not be considered replacements for,
and should be read together with, the most comparable GAAP
financial measures. Except for guidance measures, reconciliations
of these non-GAAP financial measures to the most directly
comparable GAAP financial measures can be found in the accompanying
financial schedules of the earnings release and the Investors
section of the Company's website at quarterly-results.
Copies of the financial schedules accompanying this earnings
release are available on the Company's website at
quarterly-results. These schedules include supplementary sales
data, a condensed consolidated statement of earnings,
reconciliations of non-GAAP financial measures, and sales of key
products/franchises. Additional information on Johnson &
Johnson, including adjusted income before tax by segment, a
pharmaceutical pipeline of selected compounds in late stage
development and a copy of today's earnings call presentation can
also be found in the Investors section of the Company's website at
quarterly-results.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS:
This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995 regarding, among other things: future operating
and financial performance, product development, market position and
business strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: risks related to the impact of the
COVID-19 global pandemic, such as the scope and duration of the
outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical
procedures, supply chain disruptions and other impacts to the
business, or on the Company's ability to execute business
continuity plans, as a result of the COVID-19 pandemic, economic
factors, such as interest rate and currency exchange rate
fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges inherent
in new product research and development, including uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of
commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans; the impact of
business combinations and divestitures; manufacturing difficulties
or delays, internally or within the supply chain; product efficacy
or safety concerns resulting in product recalls or regulatory
action; significant adverse litigation or government action,
including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global
health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health
care products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny
of the health care industry by government agencies. A further list
and descriptions of these risks, uncertainties and other factors
can be found in Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended December 29,
2019, including in the sections captioned "Cautionary Note
Regarding Forward-Looking Statements" and "Item 1A. Risk Factors,"
in the Company's most recently filed Quarterly Report on Form 10-Q
and the Company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Any forward-looking statement made in this release speaks
only as of the date of this release. Johnson & Johnson does not
undertake to update any forward-looking statement as a result of
new information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2020
|
|
2019
|
|
Total
|
|
Operations
|
|
Currency
|
|
2020
|
|
2019
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,556
|
|
1,394
|
|
11.6
|
%
|
11.6
|
|
-
|
|
$
4,853
|
|
4,369
|
|
11.1
|
%
|
11.1
|
|
-
|
International
|
1,958
|
|
2,075
|
|
(5.6)
|
|
(2.7)
|
|
(2.9)
|
|
5,582
|
|
5,962
|
|
(6.4)
|
|
(2.2)
|
|
(4.2)
|
|
3,514
|
|
3,469
|
|
1.3
|
|
3.0
|
|
(1.7)
|
|
10,435
|
|
10,331
|
|
1.0
|
|
3.4
|
|
(2.4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
6,438
|
|
6,340
|
|
1.5
|
|
1.5
|
|
-
|
|
18,619
|
|
17,705
|
|
5.2
|
|
5.2
|
|
-
|
International
|
4,980
|
|
4,537
|
|
9.7
|
|
8.8
|
|
0.9
|
|
14,685
|
|
13,945
|
|
5.3
|
|
7.4
|
|
(2.1)
|
|
11,418
|
|
10,877
|
|
5.0
|
|
4.6
|
|
0.4
|
|
33,304
|
|
31,650
|
|
5.2
|
|
6.1
|
|
(0.9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,092
|
|
3,057
|
|
1.2
|
|
1.2
|
|
-
|
|
7,852
|
|
9,249
|
|
(15.1)
|
|
(15.1)
|
|
-
|
International
|
3,058
|
|
3,326
|
|
(8.1)
|
|
(8.5)
|
|
0.4
|
|
8,518
|
|
10,082
|
|
(15.5)
|
|
(14.1)
|
|
(1.4)
|
|
6,150
|
|
6,383
|
|
(3.6)
|
|
(3.9)
|
|
0.3
|
|
16,370
|
|
19,331
|
|
(15.3)
|
|
(14.6)
|
|
(0.7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
11,086
|
|
10,791
|
|
2.7
|
|
2.7
|
|
-
|
|
31,324
|
|
31,323
|
|
0.0
|
|
0.0
|
|
-
|
International
|
9,996
|
|
9,938
|
|
0.6
|
|
0.6
|
|
0.0
|
|
28,785
|
|
29,989
|
|
(4.0)
|
|
(1.7)
|
|
(2.3)
|
Worldwide
|
$
21,082
|
|
20,729
|
|
1.7
|
|
1.7
|
|
0.0
|
|
$
60,109
|
|
61,312
|
|
(2.0)
|
|
(0.8)
|
|
(1.2)
|
|
|
|
|
Note:
Percentages have been calculated using actual, non-rounded figures
and, therefore, may not recalculate precisely.
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2020
|
|
2019
|
|
Total
|
|
Operations
|
|
Currency
|
|
2020
|
|
2019
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
11,086
|
|
10,791
|
|
2.7
|
%
|
2.7
|
|
-
|
|
$
31,324
|
|
31,323
|
|
0.0
|
%
|
0.0
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
4,819
|
|
4,461
|
|
8.0
|
|
4.6
|
|
3.4
|
|
13,709
|
|
13,803
|
|
(0.7)
|
|
0.1
|
|
(0.8)
|
Western Hemisphere
excluding U.S.
|
1,296
|
|
1,488
|
|
(12.9)
|
|
(1.2)
|
|
(11.7)
|
|
3,931
|
|
4,446
|
|
(11.6)
|
|
(0.4)
|
|
(11.2)
|
Asia-Pacific,
Africa
|
3,881
|
|
3,989
|
|
(2.7)
|
|
(3.2)
|
|
0.5
|
|
11,145
|
|
11,740
|
|
(5.1)
|
|
(4.3)
|
|
(0.8)
|
International
|
9,996
|
|
9,938
|
|
0.6
|
|
0.6
|
|
0.0
|
|
28,785
|
|
29,989
|
|
(4.0)
|
|
(1.7)
|
|
(2.3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
21,082
|
|
20,729
|
|
1.7
|
%
|
1.7
|
|
0.0
|
|
$
60,109
|
|
61,312
|
|
(2.0)
|
%
|
(0.8)
|
|
(1.2)
|
|
|
|
|
Note:Percentages have been calculated using
actual, non-rounded figures and, therefore, may not recalculate
precisely.
|
Johnson &
Johnson and Subsidiaries
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
THIRD
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
21,082
|
|
100.0
|
|
$
20,729
|
|
100.0
|
|
1.7
|
Cost of products
sold
|
6,972
|
|
33.1
|
|
6,867
|
|
33.1
|
|
1.5
|
Gross
Profit
|
14,110
|
|
66.9
|
|
13,862
|
|
66.9
|
|
1.8
|
Selling, marketing
and administrative expenses
|
5,431
|
|
25.8
|
|
5,374
|
|
26.0
|
|
1.1
|
Research and
development expense
|
2,840
|
|
13.5
|
|
2,599
|
|
12.5
|
|
9.3
|
In-process
research and development
|
138
|
|
0.6
|
|
-
|
|
-
|
|
|
Interest (income)
expense, net
|
32
|
|
0.1
|
|
(41)
|
|
(0.2)
|
|
|
Other (income)
expense, net
|
1,200
|
|
5.7
|
|
4,214
|
|
20.3
|
|
|
Restructuring
|
68
|
|
0.3
|
|
69
|
|
0.4
|
|
|
Earnings before
provision for taxes on income
|
4,401
|
|
20.9
|
|
1,647
|
|
7.9
|
|
167.2
|
Provision
for/(Benefit from) taxes on income
|
847
|
|
4.0
|
|
(106)
|
|
(0.6)
|
|
|
Net
earnings
|
$
3,554
|
|
16.9
|
|
$
1,753
|
|
8.5
|
|
102.7
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.33
|
|
|
|
$
0.66
|
|
|
|
101.5
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,669.3
|
|
|
|
2,669.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
19.2
|
%
|
|
|
(6.4)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
7,246
|
|
34.4
|
|
$
7,116
|
|
34.3
|
|
1.8
|
Net
earnings
|
$
5,868
|
|
27.8
|
|
$
5,672
|
|
27.4
|
|
3.5
|
Net earnings per
share (Diluted)
|
$
2.20
|
|
|
|
$
2.12
|
|
|
|
3.8
|
Effective tax
rate
|
19.0
|
%
|
|
|
20.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
Johnson &
Johnson and Subsidiaries
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
NINE
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2020
|
|
2019
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
60,109
|
|
100.0
|
|
$
61,312
|
|
100.0
|
|
(2.0)
|
Cost of products
sold
|
20,613
|
|
34.3
|
|
20,422
|
|
33.3
|
|
0.9
|
Gross
Profit
|
39,496
|
|
65.7
|
|
40,890
|
|
66.7
|
|
(3.4)
|
Selling, marketing
and administrative expenses
|
15,627
|
|
26.0
|
|
16,139
|
|
26.3
|
|
(3.2)
|
Research and
development expense
|
8,127
|
|
13.5
|
|
8,123
|
|
13.3
|
|
0.0
|
In-process
research and development
|
144
|
|
0.3
|
|
890
|
|
1.4
|
|
|
Interest (income)
expense, net
|
16
|
|
0.0
|
|
(43)
|
|
(0.1)
|
|
|
Other (income)
expense, net
|
545
|
|
0.9
|
|
2,509
|
|
4.1
|
|
|
Restructuring
|
187
|
|
0.3
|
|
162
|
|
0.3
|
|
|
Earnings before
provision for taxes on income
|
14,850
|
|
24.7
|
|
13,110
|
|
21.4
|
|
13.3
|
Provision for
taxes on income
|
1,874
|
|
3.1
|
|
2,001
|
|
3.3
|
|
(6.3)
|
Net
earnings
|
$
12,976
|
|
21.6
|
|
$
11,109
|
|
18.1
|
|
16.8
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
4.86
|
|
|
|
$
4.13
|
|
|
|
17.7
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,670.8
|
|
|
|
2,688.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
12.6
|
%
|
|
|
15.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
19,827
|
|
33.0
|
|
$
22,597
|
|
36.9
|
|
(12.3)
|
Net
earnings
|
$
16,468
|
|
27.4
|
|
$
18,283
|
|
29.8
|
|
(9.9)
|
Net earnings per
share (Diluted)
|
$
6.17
|
|
|
|
$
6.80
|
|
|
|
(9.3)
|
Effective tax
rate
|
16.9
|
%
|
|
|
19.1
|
%
|
|
|
|
|
(1)See
Reconciliation of Non-GAAP Financial Measures.
|
Johnson &
Johnson and Subsidiaries
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
Third
Quarter
|
|
Nine Months
Ended
|
(Dollars in Millions
Except Per Share Data)
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Net Earnings, after
tax- as reported
|
$3,554
|
|
$1,753
|
|
$12,976
|
|
$11,109
|
|
|
|
|
|
|
|
|
Pre-tax
Adjustments
|
|
|
|
|
|
|
|
Intangible Asset
Amortization expense
|
1,181
|
|
1,138
|
|
3,426
|
|
3,386
|
Litigation expense,
net
|
1,477
|
|
4,000
|
|
2,210
|
|
4,832
|
IPR&D
|
138
|
|
-
|
|
144
|
|
890
|
Restructuring
related
|
130
|
|
128
|
|
363
|
|
360
|
Acquisition and
Integration related ¹
|
(154)
|
|
107
|
|
(1,087)
|
|
229
|
Unrealized
(gains)/losses on securities
|
32
|
|
89
|
|
(174)
|
|
(217)
|
Medical Device
Regulation2
|
38
|
|
-
|
|
89
|
|
-
|
Other
|
3
|
|
7
|
|
6
|
|
7
|
|
|
|
|
|
|
|
|
Tax
Adjustments
|
|
|
|
|
|
|
|
Tax impact on special
item adjustments 3
|
(482)
|
|
(1,159)
|
|
(1,002)
|
|
(1,922)
|
Tax legislation and
related impacts
|
(49)
|
|
(391)
|
|
(483)
|
|
(391)
|
Adjusted Net
Earnings, after tax
|
$5,868
|
|
$5,672
|
|
$16,468
|
|
$18,283
|
Average shares
outstanding (Diluted)
|
2,669.3
|
|
2,669.9
|
|
2,670.8
|
|
2,688.1
|
Adjusted net earnings
per share (Diluted)
|
$2.20
|
|
$2.12
|
|
$6.17
|
|
$6.80
|
Operational adjusted
net earnings per share (Diluted)
|
$2.17
|
|
|
|
$6.18
|
|
|
|
|
|
Notes:
|
1
|
Acquisition and
integration related costs for 2020 primarily includes a Contingent
Consideration reversal ($165M in third quarter and $1,148M in nine
months) related to the timing of certain developmental milestones
associated with the Auris Health acquisition.
|
|
|
2
|
European Medical
Device Regulation (MDR) costs represent one-time compliance costs
for the Company's previously registered products. MDR is a
replacement of the existing European Medical Devices Directive
regulatory framework, and manufacturers of currently marketed
medical devices are required to comply with EU MDR beginning in May
2021. The Company considers the adoption of EU MDR to be a
significant one-time regulatory change and is not indicative of
on-going operations. The Company has excluded only external
third-party regulatory and consulting costs from its Medical
Devices operating segments' measures of profit and loss used for
making operating decisions and assessing performance.
|
|
|
3
|
The tax impact
related to special item adjustments reflects the current and
deferred income taxes associated with the above pre-tax special
items in arriving at adjusted earnings.
|
Johnson &
Johnson and Subsidiaries
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
Adjusted
Operational Sales Growth
|
THIRD
QUARTER 2020 ACTUAL vs. 2019 ACTUAL
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
|
|
|
|
|
|
|
WW As
Reported
|
|
1.3%
|
|
5.0%
|
|
(3.6)%
|
|
1.7%
|
U.S.
|
|
11.6%
|
|
1.5%
|
|
1.2%
|
|
2.7%
|
International
|
|
(5.6)%
|
|
9.7%
|
|
(8.1)%
|
|
0.6%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
(1.7)
|
|
0.4
|
|
0.3
|
|
0.0
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
(2.9)
|
|
0.9
|
|
0.4
|
|
0.0
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
3.0%
|
|
4.6%
|
|
(3.9)%
|
|
1.7%
|
U.S.
|
|
11.6%
|
|
1.5%
|
|
1.2%
|
|
2.7%
|
International
|
|
(2.7)%
|
|
8.8%
|
|
(8.5)%
|
|
0.6%
|
|
|
|
|
|
|
|
|
|
General
Surgery
|
|
|
|
|
|
|
|
|
Advanced
Sterilization Products
|
|
|
|
|
|
0.5
|
|
0.2
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
0.9
|
|
0.4
|
|
|
|
|
|
|
|
|
|
Baby
Care
|
|
|
|
|
|
|
|
|
Baby
Center
|
|
0.1
|
|
|
|
|
|
0.0
|
U.S.
|
|
0.4
|
|
|
|
|
|
0.1
|
International
|
|
0.0
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.0
|
|
0.1
|
|
0.0
|
|
0.1
|
U.S.
|
|
0.0
|
|
0.0
|
|
0.1
|
|
0.0
|
International
|
|
(0.1)
|
|
0.3
|
|
0.0
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
3.1%
|
|
4.7%
|
|
(3.3)%
|
|
2.0%
|
U.S.
|
|
12.0%
|
|
1.5%
|
|
1.3%
|
|
2.8%
|
International
|
|
(2.8)%
|
|
9.2%
|
|
(7.6)%
|
|
1.1%
|
|
Note:Percentages are based on actual,
non-rounded figures and may not sum
|
Johnson &
Johnson and Subsidiaries
|
Reconciliation of
Non-GAAP Financial Measure
|
|
Adjusted
Operational Sales Growth
|
NINE MONTHS
2020 ACTUAL vs. 2019 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
Health
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
|
|
|
|
|
|
|
WW As
Reported
|
|
1.0%
|
|
5.2%
|
|
(15.3)%
|
|
(2.0)%
|
U.S.
|
|
11.1%
|
|
5.2%
|
|
(15.1)%
|
|
0.0%
|
International
|
|
(6.4)%
|
|
5.3%
|
|
(15.5)%
|
|
(4.0)%
|
|
|
|
|
|
|
|
|
|
WW
Currency
|
|
(2.4)
|
|
(0.9)
|
|
(0.7)
|
|
(1.2)
|
U.S.
|
|
-
|
|
-
|
|
-
|
|
-
|
International
|
|
(4.2)
|
|
(2.1)
|
|
(1.4)
|
|
(2.3)
|
|
|
|
|
|
|
|
|
|
WW
Operational
|
|
3.4%
|
|
6.1%
|
|
(14.6)%
|
|
(0.8)%
|
U.S.
|
|
11.1%
|
|
5.2%
|
|
(15.1)%
|
|
0.0%
|
International
|
|
(2.2)%
|
|
7.4%
|
|
(14.1)%
|
|
(1.7)%
|
|
|
|
|
|
|
|
|
|
Skin Health /
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci Labo -
Japan
|
|
(0.1)
|
|
|
|
|
|
0.0
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
(0.2)
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
General
Surgery
|
|
|
|
|
|
|
|
|
Advanced
Sterilization Products
|
|
|
|
|
|
0.9
|
|
0.3
|
U.S.
|
|
|
|
|
|
0.8
|
|
0.3
|
International
|
|
|
|
|
|
0.9
|
|
0.4
|
|
|
|
|
|
|
|
|
|
Baby
Care
|
|
|
|
|
|
|
|
|
Baby
Center
|
|
0.2
|
|
|
|
|
|
0.0
|
U.S.
|
|
0.6
|
|
|
|
|
|
0.1
|
International
|
|
0.0
|
|
|
|
|
|
0.0
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
(0.1)
|
|
0.2
|
|
0.0
|
|
0.1
|
U.S.
|
|
0.0
|
|
0.0
|
|
0.0
|
|
0.0
|
International
|
|
(0.1)
|
|
0.3
|
|
0.0
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Adjusted
Operational
|
|
3.4%
|
|
6.3%
|
|
(13.7)%
|
|
(0.4)%
|
U.S.
|
|
11.7%
|
|
5.2%
|
|
(14.3)%
|
|
0.4%
|
International
|
|
(2.6)%
|
|
7.7%
|
|
(13.1)%
|
|
(1.3)%
|
|
Note:Percentages are based on actual,
non-rounded figures and may not sum
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
|
|
NINE
MONTHS
|
|
|
%
Change
|
|
|
|
|
%
Change
|
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER HEALTH
SEGMENT (2,3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
601
|
|
477
|
26.0%
|
26.0%
|
-
|
|
|
|
|
$
1,917
|
|
1,468
|
30.6%
|
30.6%
|
-
|
Intl
|
|
541
|
|
621
|
-12.9%
|
-12.9%
|
0.0%
|
|
|
|
|
1,722
|
|
1,781
|
-3.3%
|
-0.6%
|
-2.7%
|
WW
|
|
1,142
|
|
1,098
|
4.0%
|
4.0%
|
0.0%
|
|
|
|
|
3,639
|
|
3,249
|
12.0%
|
13.5%
|
-1.5%
|
SKIN HEALTH /
BEAUTY(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
572
|
|
559
|
2.4%
|
2.4%
|
-
|
|
|
|
|
1,767
|
|
1,810
|
-2.4%
|
-2.4%
|
-
|
Intl
|
|
577
|
|
592
|
-2.7%
|
-0.5%
|
-2.2%
|
|
|
|
|
1,506
|
|
1,633
|
-7.8%
|
-4.9%
|
-2.9%
|
WW
|
|
1,149
|
|
1,151
|
-0.2%
|
0.9%
|
-1.1%
|
|
|
|
|
3,273
|
|
3,443
|
-5.0%
|
-3.6%
|
-1.4%
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
164
|
|
156
|
5.5%
|
5.5%
|
-
|
|
|
|
|
510
|
|
462
|
10.4%
|
10.4%
|
-
|
Intl
|
|
248
|
|
223
|
10.7%
|
14.4%
|
-3.7%
|
|
|
|
|
694
|
|
673
|
3.0%
|
7.9%
|
-4.9%
|
WW
|
|
412
|
|
379
|
8.5%
|
10.8%
|
-2.3%
|
|
|
|
|
1,204
|
|
1,135
|
6.0%
|
8.9%
|
-2.9%
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
91
|
|
91
|
-1.0%
|
-1.0%
|
-
|
|
|
|
|
279
|
|
277
|
0.5%
|
0.5%
|
-
|
Intl
|
|
302
|
|
326
|
-7.2%
|
-0.6%
|
-6.6%
|
|
|
|
|
831
|
|
977
|
-14.9%
|
-8.6%
|
-6.3%
|
WW
|
|
393
|
|
417
|
-5.9%
|
-0.7%
|
-5.2%
|
|
|
|
|
1,110
|
|
1,254
|
-11.5%
|
-6.6%
|
-4.9%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3
|
|
3
|
-6.9%
|
-6.9%
|
-
|
|
|
|
|
10
|
|
9
|
7.3%
|
7.3%
|
-
|
Intl
|
|
227
|
|
252
|
-9.6%
|
-4.0%
|
-5.6%
|
|
|
|
|
654
|
|
724
|
-9.6%
|
-2.8%
|
-6.8%
|
WW
|
|
230
|
|
255
|
-9.6%
|
-4.1%
|
-5.5%
|
|
|
|
|
664
|
|
733
|
-9.4%
|
-2.7%
|
-6.7%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
125
|
|
109
|
15.2%
|
15.2%
|
-
|
|
|
|
|
370
|
|
343
|
8.0%
|
8.0%
|
-
|
Intl
|
|
64
|
|
59
|
7.4%
|
10.3%
|
-2.9%
|
|
|
|
|
175
|
|
173
|
1.3%
|
5.4%
|
-4.1%
|
WW
|
|
189
|
|
168
|
12.5%
|
13.5%
|
-1.0%
|
|
|
|
|
545
|
|
516
|
5.8%
|
7.2%
|
-1.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL CONSUMER
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,556
|
|
1,394
|
11.6%
|
11.6%
|
-
|
|
|
|
|
4,853
|
|
4,369
|
11.1%
|
11.1%
|
-
|
Intl
|
|
1,958
|
|
2,075
|
-5.6%
|
-2.7%
|
-2.9%
|
|
|
|
|
5,582
|
|
5,962
|
-6.4%
|
-2.2%
|
-4.2%
|
WW
|
|
$
3,514
|
|
3,469
|
1.3%
|
3.0%
|
-1.7%
|
|
|
|
|
$
10,435
|
|
10,331
|
1.0%
|
3.4%
|
-2.4%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
|
|
NINE
MONTHS
|
|
|
|
%
Change
|
|
|
|
|
%
Change
|
PHARMACEUTICAL
SEGMENT (2,5)
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
2,558
|
|
2,582
|
-0.9%
|
-0.9%
|
-
|
|
|
|
|
$
7,330
|
|
7,124
|
2.9%
|
2.9%
|
-
|
Intl
|
|
1,230
|
|
1,129
|
9.0%
|
8.4%
|
0.6%
|
|
|
|
|
3,619
|
|
3,304
|
9.5%
|
11.9%
|
-2.4%
|
WW
|
|
3,789
|
|
3,711
|
2.1%
|
1.9%
|
0.2%
|
|
|
|
|
10,950
|
|
10,428
|
5.0%
|
5.7%
|
-0.7%
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
634
|
|
749
|
-15.4%
|
-15.4%
|
-
|
|
|
|
|
1,852
|
|
2,324
|
-20.3%
|
-20.3%
|
-
|
US Exports
(6)
|
|
78
|
|
88
|
-11.3%
|
-11.3%
|
-
|
|
|
|
|
321
|
|
226
|
42.1%
|
42.1%
|
-
|
Intl
|
|
209
|
|
299
|
-30.1%
|
-28.0%
|
-2.1%
|
|
|
|
|
673
|
|
795
|
-15.3%
|
-11.6%
|
-3.7%
|
WW
|
|
921
|
|
1,136
|
-18.9%
|
-18.4%
|
-0.5%
|
|
|
|
|
2,846
|
|
3,345
|
-14.9%
|
-14.0%
|
-0.9%
|
SIMPONI / SIMPONI
ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
312
|
|
313
|
-0.4%
|
-0.4%
|
-
|
|
|
|
|
840
|
|
857
|
-2.0%
|
-2.0%
|
-
|
Intl
|
|
280
|
|
273
|
2.4%
|
2.2%
|
0.2%
|
|
|
|
|
827
|
|
816
|
1.3%
|
3.9%
|
-2.6%
|
WW
|
|
592
|
|
586
|
0.9%
|
0.8%
|
0.1%
|
|
|
|
|
1,667
|
|
1,673
|
-0.4%
|
0.9%
|
-1.3%
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,313
|
|
1,212
|
8.4%
|
8.4%
|
-
|
|
|
|
|
3,668
|
|
3,152
|
16.4%
|
16.4%
|
-
|
Intl
|
|
634
|
|
487
|
30.3%
|
28.1%
|
2.2%
|
|
|
|
|
1,795
|
|
1,509
|
19.0%
|
20.6%
|
-1.6%
|
WW
|
|
1,947
|
|
1,698
|
14.7%
|
14.0%
|
0.7%
|
|
|
|
|
5,463
|
|
4,661
|
17.2%
|
17.7%
|
-0.5%
|
TREMFYA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
222
|
|
221
|
0.4%
|
0.4%
|
-
|
|
|
|
|
650
|
|
565
|
15.0%
|
15.0%
|
-
|
Intl
|
|
105
|
|
69
|
54.4%
|
50.4%
|
4.0%
|
|
|
|
|
316
|
|
177
|
78.7%
|
79.1%
|
-0.4%
|
WW
|
|
327
|
|
290
|
13.1%
|
12.2%
|
0.9%
|
|
|
|
|
965
|
|
742
|
30.2%
|
30.3%
|
-0.1%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
3
|
|
2
|
35.6%
|
44.6%
|
-9.0%
|
|
|
|
|
9
|
|
8
|
12.4%
|
19.1%
|
-6.7%
|
WW
|
|
3
|
|
2
|
35.6%
|
44.6%
|
-9.0%
|
|
|
|
|
9
|
|
8
|
12.4%
|
19.1%
|
-6.7%
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
413
|
|
418
|
-1.1%
|
-1.1%
|
-
|
|
|
|
|
1,265
|
|
1,162
|
8.9%
|
8.9%
|
-
|
Intl
|
|
451
|
|
421
|
7.0%
|
6.3%
|
0.7%
|
|
|
|
|
1,397
|
|
1,385
|
0.9%
|
3.8%
|
-2.9%
|
WW
|
|
864
|
|
839
|
3.0%
|
2.6%
|
0.4%
|
|
|
|
|
2,662
|
|
2,547
|
4.5%
|
6.1%
|
-1.6%
|
EDURANT /
rilpivirine
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
11
|
|
12
|
-12.0%
|
-12.0%
|
-
|
|
|
|
|
33
|
|
36
|
-8.6%
|
-8.6%
|
-
|
Intl
|
|
226
|
|
206
|
9.3%
|
5.0%
|
4.3%
|
|
|
|
|
684
|
|
603
|
13.3%
|
13.8%
|
-0.5%
|
WW
|
|
236
|
|
218
|
8.1%
|
4.1%
|
4.0%
|
|
|
|
|
716
|
|
639
|
12.1%
|
12.6%
|
-0.5%
|
PREZISTA / PREZCOBIX
/ REZOLSTA / SYMTUZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
379
|
|
373
|
1.5%
|
1.5%
|
-
|
|
|
|
|
1,154
|
|
1,032
|
11.8%
|
11.8%
|
-
|
Intl
|
|
147
|
|
135
|
9.1%
|
12.1%
|
-3.0%
|
|
|
|
|
461
|
|
534
|
-13.7%
|
-8.8%
|
-4.9%
|
WW
|
|
526
|
|
508
|
3.5%
|
4.3%
|
-0.8%
|
|
|
|
|
1,615
|
|
1,566
|
3.1%
|
4.8%
|
-1.7%
|
OTHER INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
24
|
|
33
|
-26.6%
|
-26.6%
|
-
|
|
|
|
|
79
|
|
94
|
-16.6%
|
-16.6%
|
-
|
Intl
|
|
78
|
|
80
|
-2.3%
|
-0.4%
|
-1.9%
|
|
|
|
|
252
|
|
248
|
1.8%
|
6.3%
|
-4.5%
|
WW
|
|
102
|
|
113
|
-9.4%
|
-8.1%
|
-1.3%
|
|
|
|
|
331
|
|
342
|
-3.2%
|
0.0%
|
-3.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
|
|
NINE
MONTHS
|
|
|
%
Change
|
|
|
|
|
%
Change
|
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
759
|
|
785
|
-3.5%
|
-3.5%
|
-
|
|
|
|
|
2,285
|
|
2,172
|
5.2%
|
5.2%
|
-
|
Intl
|
|
846
|
|
810
|
4.5%
|
4.1%
|
0.4%
|
|
|
|
|
2,565
|
|
2,590
|
-1.0%
|
0.9%
|
-1.9%
|
WW
|
|
1,605
|
|
1,595
|
0.6%
|
0.4%
|
0.2%
|
|
|
|
|
4,850
|
|
4,762
|
1.8%
|
2.9%
|
-1.1%
|
CONCERTA /
Methylphenidate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
43
|
|
84
|
-49.2%
|
-49.2%
|
-
|
|
|
|
|
150
|
|
196
|
-23.6%
|
-23.6%
|
-
|
Intl
|
|
107
|
|
109
|
-2.0%
|
-1.7%
|
-0.3%
|
|
|
|
|
319
|
|
348
|
-8.2%
|
-6.4%
|
-1.8%
|
WW
|
|
149
|
|
193
|
-22.6%
|
-22.5%
|
-0.1%
|
|
|
|
|
469
|
|
544
|
-13.8%
|
-12.6%
|
-1.2%
|
INVEGA SUSTENNA /
XEPLION /
INVEGA TRINZA / TREVICTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
585
|
|
554
|
5.6%
|
5.6%
|
-
|
|
|
|
|
1,704
|
|
1,543
|
10.5%
|
10.5%
|
-
|
Intl
|
|
341
|
|
297
|
14.9%
|
12.6%
|
2.3%
|
|
|
|
|
983
|
|
916
|
7.3%
|
8.6%
|
-1.3%
|
WW
|
|
926
|
|
851
|
8.8%
|
8.0%
|
0.8%
|
|
|
|
|
2,688
|
|
2,459
|
9.3%
|
9.8%
|
-0.5%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
70
|
|
79
|
-11.0%
|
-11.0%
|
-
|
|
|
|
|
220
|
|
237
|
-6.9%
|
-6.9%
|
-
|
Intl
|
|
81
|
|
89
|
-7.8%
|
-8.9%
|
1.1%
|
|
|
|
|
254
|
|
292
|
-12.7%
|
-11.0%
|
-1.7%
|
WW
|
|
152
|
|
167
|
-9.3%
|
-9.9%
|
0.6%
|
|
|
|
|
475
|
|
528
|
-10.1%
|
-9.2%
|
-0.9%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
60
|
|
68
|
-11.3%
|
-11.3%
|
-
|
|
|
|
|
210
|
|
196
|
7.1%
|
7.1%
|
-
|
Intl
|
|
317
|
|
316
|
0.3%
|
1.7%
|
-1.4%
|
|
|
|
|
1,008
|
|
1,035
|
-2.6%
|
-0.1%
|
-2.5%
|
WW
|
|
377
|
|
384
|
-1.8%
|
-0.6%
|
-1.2%
|
|
|
|
|
1,218
|
|
1,231
|
-1.1%
|
1.1%
|
-2.2%
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,267
|
|
1,171
|
8.2%
|
8.2%
|
-
|
|
|
|
|
3,623
|
|
3,146
|
15.2%
|
15.2%
|
-
|
Intl
|
|
1,862
|
|
1,590
|
17.1%
|
15.5%
|
1.6%
|
|
|
|
|
5,310
|
|
4,830
|
9.9%
|
11.8%
|
-1.9%
|
WW
|
|
3,129
|
|
2,761
|
13.3%
|
12.4%
|
0.9%
|
|
|
|
|
8,933
|
|
7,976
|
12.0%
|
13.1%
|
-1.1%
|
DARZALEX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
585
|
|
402
|
46.0%
|
46.0%
|
-
|
|
|
|
|
1,540
|
|
1,123
|
37.2%
|
37.2%
|
-
|
Intl
|
|
514
|
|
363
|
41.5%
|
40.5%
|
1.0%
|
|
|
|
|
1,397
|
|
1,045
|
33.7%
|
36.7%
|
-3.0%
|
WW
|
|
1,099
|
|
765
|
43.8%
|
43.4%
|
0.4%
|
|
|
|
|
2,937
|
|
2,168
|
35.5%
|
37.0%
|
-1.5%
|
ERLEADA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
152
|
|
74
|
*
|
*
|
-
|
|
|
|
|
407
|
|
194
|
*
|
*
|
-
|
Intl
|
|
55
|
|
12
|
*
|
*
|
*
|
|
|
|
|
112
|
|
22
|
*
|
*
|
*
|
WW
|
|
206
|
|
86
|
*
|
*
|
*
|
|
|
|
|
519
|
|
216
|
*
|
*
|
*
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
450
|
|
447
|
0.7%
|
0.7%
|
-
|
|
|
|
|
1,329
|
|
1,163
|
14.2%
|
14.2%
|
-
|
Intl
|
|
581
|
|
475
|
22.5%
|
21.2%
|
1.3%
|
|
|
|
|
1,682
|
|
1,373
|
22.5%
|
25.2%
|
-2.7%
|
WW
|
|
1,031
|
|
921
|
11.9%
|
11.2%
|
0.7%
|
|
|
|
|
3,011
|
|
2,536
|
18.7%
|
20.2%
|
-1.5%
|
VELCADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
105
|
|
149
|
-30.1%
|
-30.8%
|
0.7%
|
|
|
|
|
311
|
|
636
|
-51.2%
|
-50.7%
|
-0.5%
|
WW
|
|
105
|
|
149
|
-30.1%
|
-30.8%
|
0.7%
|
|
|
|
|
311
|
|
636
|
-51.2%
|
-50.7%
|
-0.5%
|
ZYTIGA / abiraterone
acetate
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
58
|
|
233
|
-75.2%
|
-75.2%
|
-
|
|
|
|
|
284
|
|
616
|
-53.9%
|
-53.9%
|
-
|
Intl
|
|
532
|
|
508
|
4.8%
|
2.2%
|
2.6%
|
|
|
|
|
1,564
|
|
1,502
|
4.1%
|
4.8%
|
-0.7%
|
WW
|
|
590
|
|
741
|
-20.4%
|
-22.1%
|
1.7%
|
|
|
|
|
1,848
|
|
2,118
|
-12.7%
|
-12.3%
|
-0.4%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
21
|
|
17
|
35.3%
|
35.3%
|
-
|
|
|
|
|
63
|
|
51
|
25.8%
|
25.8%
|
-
|
Intl
|
|
76
|
|
83
|
-8.8%
|
-10.1%
|
1.3%
|
|
|
|
|
244
|
|
252
|
-3.1%
|
-1.1%
|
-2.0%
|
WW
|
|
98
|
|
100
|
-1.7%
|
-2.8%
|
1.1%
|
|
|
|
|
308
|
|
303
|
1.7%
|
3.3%
|
-1.6%
|
PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
510
|
|
427
|
19.4%
|
19.4%
|
-
|
|
|
|
|
1,541
|
|
1,296
|
18.9%
|
18.9%
|
-
|
Intl
|
|
239
|
|
227
|
5.2%
|
3.7%
|
1.5%
|
|
|
|
|
742
|
|
704
|
5.3%
|
6.5%
|
-1.2%
|
WW
|
|
749
|
|
654
|
14.5%
|
13.9%
|
0.6%
|
|
|
|
|
2,283
|
|
2,000
|
14.1%
|
14.6%
|
-0.5%
|
OPSUMIT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
244
|
|
206
|
18.1%
|
18.1%
|
-
|
|
|
|
|
729
|
|
581
|
25.3%
|
25.3%
|
-
|
Intl
|
|
148
|
|
140
|
5.5%
|
3.9%
|
1.6%
|
|
|
|
|
458
|
|
419
|
9.3%
|
10.7%
|
-1.4%
|
WW
|
|
392
|
|
347
|
13.0%
|
12.3%
|
0.7%
|
|
|
|
|
1,187
|
|
1,001
|
18.6%
|
19.2%
|
-0.6%
|
UPTRAVI
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
226
|
|
185
|
22.4%
|
22.4%
|
-
|
|
|
|
|
692
|
|
536
|
29.1%
|
29.1%
|
-
|
Intl
|
|
34
|
|
25
|
32.3%
|
28.9%
|
3.4%
|
|
|
|
|
100
|
|
75
|
33.1%
|
34.6%
|
-1.5%
|
WW
|
|
260
|
|
210
|
23.6%
|
23.2%
|
0.4%
|
|
|
|
|
792
|
|
611
|
29.6%
|
29.8%
|
-0.2%
|
OTHER PULMONARY
HYPERTENSION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
40
|
|
36
|
11.5%
|
11.5%
|
-
|
|
|
|
|
121
|
|
179
|
-32.3%
|
-32.3%
|
-
|
Intl
|
|
57
|
|
61
|
-6.7%
|
-7.4%
|
0.7%
|
|
|
|
|
183
|
|
210
|
-12.7%
|
-11.9%
|
-0.8%
|
WW
|
|
97
|
|
96
|
0.1%
|
-0.3%
|
0.4%
|
|
|
|
|
304
|
|
388
|
-21.7%
|
-21.3%
|
-0.4%
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
931
|
|
955
|
-2.6%
|
-2.6%
|
-
|
|
|
|
|
2,574
|
|
2,804
|
-8.2%
|
-8.2%
|
-
|
Intl
|
|
351
|
|
360
|
-2.7%
|
-2.4%
|
-0.3%
|
|
|
|
|
1,052
|
|
1,131
|
-7.1%
|
-4.6%
|
-2.5%
|
WW
|
|
1,281
|
|
1,316
|
-2.6%
|
-2.5%
|
-0.1%
|
|
|
|
|
3,625
|
|
3,936
|
-7.9%
|
-7.2%
|
-0.7%
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
630
|
|
613
|
2.9%
|
2.9%
|
-
|
|
|
|
|
1,716
|
|
1,704
|
0.7%
|
0.7%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
630
|
|
613
|
2.9%
|
2.9%
|
-
|
|
|
|
|
1,716
|
|
1,704
|
0.7%
|
0.7%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
156
|
|
125
|
24.7%
|
24.7%
|
-
|
|
|
|
|
405
|
|
411
|
-1.6%
|
-1.6%
|
-
|
Intl
|
|
68
|
|
55
|
24.7%
|
25.2%
|
-0.5%
|
|
|
|
|
173
|
|
147
|
18.0%
|
20.7%
|
-2.7%
|
WW
|
|
224
|
|
179
|
24.7%
|
24.9%
|
-0.2%
|
|
|
|
|
578
|
|
558
|
3.6%
|
4.3%
|
-0.7%
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
69
|
|
126
|
-45.4%
|
-45.4%
|
-
|
|
|
|
|
215
|
|
387
|
-44.5%
|
-44.5%
|
-
|
Intl
|
|
63
|
|
72
|
-12.2%
|
-13.0%
|
0.8%
|
|
|
|
|
208
|
|
220
|
-5.5%
|
-4.3%
|
-1.2%
|
WW
|
|
132
|
|
198
|
-33.3%
|
-33.6%
|
0.3%
|
|
|
|
|
423
|
|
607
|
-30.4%
|
-29.9%
|
-0.5%
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
75
|
|
91
|
-17.9%
|
-17.9%
|
-
|
|
|
|
|
238
|
|
302
|
-21.4%
|
-21.4%
|
-
|
Intl
|
|
219
|
|
234
|
-6.2%
|
-5.5%
|
-0.7%
|
|
|
|
|
670
|
|
765
|
-12.3%
|
-9.5%
|
-2.8%
|
WW
|
|
294
|
|
325
|
-9.5%
|
-9.0%
|
-0.5%
|
|
|
|
|
908
|
|
1,067
|
-14.9%
|
-12.9%
|
-2.0%
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
6,438
|
|
6,340
|
1.5%
|
1.5%
|
-
|
|
|
|
|
18,619
|
|
17,705
|
5.2%
|
5.2%
|
-
|
Intl
|
|
4,980
|
|
4,537
|
9.7%
|
8.8%
|
0.9%
|
|
|
|
|
14,685
|
|
13,945
|
5.3%
|
7.4%
|
-2.1%
|
WW
|
|
$
11,418
|
|
10,877
|
5.0%
|
4.6%
|
0.4%
|
|
|
|
|
$
33,304
|
|
31,650
|
5.2%
|
6.1%
|
-0.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
|
|
NINE
MONTHS
|
|
|
%
Change
|
|
|
|
|
%
Change
|
MEDICAL DEVICES
SEGMENT (2,5)
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
2020
|
|
2019
|
Reported
|
Operational
(1)
|
Currency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INTERVENTIONAL
SOLUTIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
399
|
|
357
|
11.8%
|
11.8%
|
-
|
|
|
|
|
1,019
|
|
1,066
|
-4.4%
|
-4.4%
|
-
|
Intl
|
|
437
|
|
382
|
14.0%
|
12.9%
|
1.1%
|
|
|
|
|
1,134
|
|
1,156
|
-2.0%
|
-1.0%
|
-1.0%
|
WW
|
|
836
|
|
741
|
12.9%
|
12.4%
|
0.5%
|
|
|
|
|
2,153
|
|
2,223
|
-3.1%
|
-2.7%
|
-0.4%
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,308
|
|
1,301
|
0.6%
|
0.6%
|
-
|
|
|
|
|
3,427
|
|
3,950
|
-13.2%
|
-13.2%
|
-
|
Intl
|
|
774
|
|
837
|
-7.5%
|
-9.0%
|
1.5%
|
|
|
|
|
2,145
|
|
2,616
|
-18.0%
|
-16.9%
|
-1.1%
|
WW
|
|
2,083
|
|
2,138
|
-2.6%
|
-3.1%
|
0.5%
|
|
|
|
|
5,572
|
|
6,566
|
-15.1%
|
-14.7%
|
-0.4%
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
221
|
|
204
|
8.7%
|
8.7%
|
-
|
|
|
|
|
564
|
|
633
|
-10.9%
|
-10.9%
|
-
|
Intl
|
|
124
|
|
133
|
-7.2%
|
-8.4%
|
1.2%
|
|
|
|
|
344
|
|
428
|
-19.8%
|
-18.3%
|
-1.5%
|
WW
|
|
345
|
|
336
|
2.4%
|
1.9%
|
0.5%
|
|
|
|
|
908
|
|
1,061
|
-14.5%
|
-13.9%
|
-0.6%
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
205
|
|
209
|
-1.9%
|
-1.9%
|
-
|
|
|
|
|
527
|
|
650
|
-19.0%
|
-19.0%
|
-
|
Intl
|
|
102
|
|
136
|
-24.8%
|
-26.4%
|
1.6%
|
|
|
|
|
298
|
|
435
|
-31.5%
|
-30.7%
|
-0.8%
|
WW
|
|
308
|
|
344
|
-10.9%
|
-11.6%
|
0.7%
|
|
|
|
|
825
|
|
1,085
|
-24.0%
|
-23.7%
|
-0.3%
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
433
|
|
415
|
4.2%
|
4.2%
|
-
|
|
|
|
|
1,194
|
|
1,239
|
-3.6%
|
-3.6%
|
-
|
Intl
|
|
253
|
|
262
|
-3.4%
|
-4.7%
|
1.3%
|
|
|
|
|
698
|
|
795
|
-12.2%
|
-10.9%
|
-1.3%
|
WW
|
|
685
|
|
677
|
1.3%
|
0.7%
|
0.6%
|
|
|
|
|
1,892
|
|
2,034
|
-7.0%
|
-6.5%
|
-0.5%
|
SPINE, SPORTS &
OTHER(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
449
|
|
472
|
-4.9%
|
-4.9%
|
-
|
|
|
|
|
1,142
|
|
1,427
|
-20.0%
|
-20.0%
|
-
|
Intl
|
|
295
|
|
306
|
-3.4%
|
-5.0%
|
1.6%
|
|
|
|
|
805
|
|
957
|
-15.8%
|
-14.9%
|
-0.9%
|
WW
|
|
745
|
|
778
|
-4.3%
|
-5.0%
|
0.7%
|
|
|
|
|
1,947
|
|
2,384
|
-18.3%
|
-18.0%
|
-0.3%
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
913
|
|
940
|
-3.0%
|
-3.0%
|
-
|
|
|
|
|
2,247
|
|
2,867
|
-21.7%
|
-21.7%
|
-
|
Intl
|
|
1,239
|
|
1,371
|
-9.6%
|
-9.5%
|
-0.1%
|
|
|
|
|
3,556
|
|
4,192
|
-15.2%
|
-13.1%
|
-2.1%
|
WW
|
|
2,152
|
|
2,311
|
-6.9%
|
-6.9%
|
0.0%
|
|
|
|
|
5,803
|
|
7,059
|
-17.8%
|
-16.6%
|
-1.2%
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
421
|
|
409
|
3.0%
|
3.0%
|
-
|
|
|
|
|
1,079
|
|
1,209
|
-10.7%
|
-10.7%
|
-
|
Intl
|
|
579
|
|
602
|
-3.9%
|
-4.1%
|
0.2%
|
|
|
|
|
1,644
|
|
1,811
|
-9.2%
|
-7.3%
|
-1.9%
|
WW
|
|
1,000
|
|
1,010
|
-1.1%
|
-1.2%
|
0.1%
|
|
|
|
|
2,723
|
|
3,019
|
-9.8%
|
-8.7%
|
-1.1%
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
492
|
|
531
|
-7.6%
|
-7.6%
|
-
|
|
|
|
|
1,168
|
|
1,658
|
-29.6%
|
-29.6%
|
-
|
Intl
|
|
660
|
|
769
|
-14.1%
|
-13.8%
|
-0.3%
|
|
|
|
|
1,912
|
|
2,381
|
-19.7%
|
-17.5%
|
-2.2%
|
WW
|
|
1,152
|
|
1,301
|
-11.4%
|
-11.3%
|
-0.1%
|
|
|
|
|
3,080
|
|
4,040
|
-23.8%
|
-22.5%
|
-1.3%
|
VISION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
473
|
|
459
|
3.1%
|
3.1%
|
-
|
|
|
|
|
1,160
|
|
1,366
|
-15.1%
|
-15.1%
|
-
|
Intl
|
|
608
|
|
734
|
-17.2%
|
-17.4%
|
0.2%
|
|
|
|
|
1,683
|
|
2,117
|
-20.5%
|
-19.6%
|
-0.9%
|
WW
|
|
1,081
|
|
1,193
|
-9.4%
|
-9.5%
|
0.1%
|
|
|
|
|
2,843
|
|
3,483
|
-18.4%
|
-17.8%
|
-0.6%
|
CONTACT LENSES /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
375
|
|
339
|
10.9%
|
10.9%
|
-
|
|
|
|
|
924
|
|
993
|
-6.9%
|
-6.9%
|
-
|
Intl
|
|
455
|
|
555
|
-18.1%
|
-18.2%
|
0.1%
|
|
|
|
|
1,274
|
|
1,566
|
-18.7%
|
-17.8%
|
-0.9%
|
WW
|
|
830
|
|
893
|
-7.1%
|
-7.2%
|
0.1%
|
|
|
|
|
2,198
|
|
2,559
|
-14.1%
|
-13.6%
|
-0.5%
|
SURGICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
98
|
|
120
|
-18.9%
|
-18.9%
|
-
|
|
|
|
|
236
|
|
373
|
-36.8%
|
-36.8%
|
-
|
Intl
|
|
153
|
|
180
|
-14.6%
|
-14.8%
|
0.2%
|
|
|
|
|
409
|
|
551
|
-25.7%
|
-24.8%
|
-0.9%
|
WW
|
|
251
|
|
299
|
-16.3%
|
-16.4%
|
0.1%
|
|
|
|
|
645
|
|
923
|
-30.2%
|
-29.6%
|
-0.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,092
|
|
3,057
|
1.2%
|
1.2%
|
-
|
|
|
|
|
7,852
|
|
9,249
|
-15.1%
|
-15.1%
|
-
|
Intl
|
|
3,058
|
|
3,326
|
-8.1%
|
-8.5%
|
0.4%
|
|
|
|
|
8,518
|
|
10,082
|
-15.5%
|
-14.1%
|
-1.4%
|
WW
|
|
$
6,150
|
|
6,383
|
-3.6%
|
-3.9%
|
0.3%
|
|
|
|
|
$
16,370
|
|
19,331
|
-15.3%
|
-14.6%
|
-0.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Note: Columns
and rows within tables may not add due to rounding. Percentages
have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
|
|
|
|
* Percentage greater
than 100% or not meaningful
|
|
(6) Reported as U.S.
sales
|
(1) Operational
growth excludes the effect of translational currency
|
|
(7) Previously
referred to as Spine & Other
|
(2)
Unaudited
|
|
|
(3) Previously
referred to as Consumer
|
|
|
(4) Previously
referred to as Beauty
|
|
|
(5) Certain prior
year amounts have been reclassified to conform to current year
product disclosures
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2020-third-quarter-results-301150947.html
SOURCE Johnson & Johnson